Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines

doi:10.3892/ol.2019.10643

	Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
	Wang, Hui-Li 1; Liu, Yan-Chun2 ; Long, Ming-Peng 1; Zheng, Chuan 1; Yang, Jia-Hui 1
通讯作者	Zheng, Chuan(alonzc@163.com) ; Yang, Jia-Hui(yangjiahui@cdutcm.edu.cn)
	2019-09-01
发表期刊	ONCOLOGY LETTERS
ISSN	1792-1074
卷号	18 期号:3 页码:2977-2984
摘要	Treatment strategies involving tyrosine kinase inhibitors (TKIs) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have advanced significantly; however, challenges still remain regarding the development of resistance. It has been reported that receptor tyrosine kinase-like orphan receptor 1 (ROR1) acts as a hepatocyte growth factor receptor (MET) and c-Src substrate, and that the extracellular domain of ROR1 is associated with EGFR to sustain EGFR-ERBB3-PI3K signaling. Our previous study reported that blocking ROR1 significantly decreased the activity of key signal molecules in the AKT/mammalian target of rapamycin (mTOR) signaling pathway, which was associated with a significant increase of apoptosis and significant decrease of proliferation of lung adenocarcinoma cells. The present study hypothesized that inhibiting ROR1 could potentially prevent erlotinib resistance in NSCLC cell lines. Investigations were performed with two erlotinib-resistant cell lines XLA-07 and NCI-H1975, and an erlotinib-acquired-resistant cell line PC-9erlo, which was developed from its parental cell line PC-9. It was identified that the inhibition of ROR1 via small interfering RNA treatment significantly improved the anti-proliferation and apoptosis-inducing roles of erlotinib in TKI-resistant tumor cells. This was in accordance with the activity of key molecules of the AKT/mTOR signaling pathway, including glycogen synthase kinase-3 alpha/beta (GSK-3 alpha/beta), phosphatase and tensin homolog (PTEN), AKT, mTOR and ribosomal protein S6 kinase beta-1 (p70S6K). The current data suggest that targeting ROR1 is a potential novel treatment strategy for patients with ROR1-positive NSCLC, particularly those with acquired resistance to EGFR-TKI.
关键词	receptor tyrosine kinase-like orphan receptor 1 lung adenocarcinoma erlotinib resistance AKT mammalian target of rapamycin small interfering RNA
DOI	10.3892/ol.2019.10643
收录类别	SCI
语种	英语
WOS记录号	WOS:000487675500101
引用统计
文献类型	期刊论文
条目标识符	http://ir.kib.ac.cn/handle/151853/69450
专题	植物化学与西部植物资源持续利用国家重点实验室
通讯作者	Zheng, Chuan; Yang, Jia-Hui
作者单位	1.Chengdu Univ Tradit Chinese Med, Sch Basic Med, 1166 Liutai Ave, Chengdu 611137, Sichuan, Peoples R China 2.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China
推荐引用方式 GB/T 7714	Wang, Hui-Li,Liu, Yan-Chun,Long, Ming-Peng,et al. Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines[J]. ONCOLOGY LETTERS,2019,18(3):2977-2984.
APA	Wang, Hui-Li,Liu, Yan-Chun,Long, Ming-Peng,Zheng, Chuan,&Yang, Jia-Hui.(2019).Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines.ONCOLOGY LETTERS,18(3),2977-2984.
MLA	Wang, Hui-Li,et al."Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines".ONCOLOGY LETTERS 18.3(2019):2977-2984.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
Wang-2019-Blocking R（667KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	浏览下载